Information

This study evaluated 134 patients with mild to moderate COVID-19 who met predefined inclusion and exclusion criteria. Participants were randomly assigned into two groups: an intervention group receiving AVIMAC in addition to standard of care (SOC), and a control group receiving SOC alone. Patients in the intervention group were administered AVIMAC at a dose of 300 mg three times daily after meals for six days, alongside standard treatment. The study was conducted from 3 October 2020, when the first participant was enrolled, until 25 January 2021, corresponding to the final visit of the last enrolled participant.

PT Neumedik

Type of Study

Stakeholders Involved

COVID-19 Clinical Trial

Background

Mild to moderate COVID-19 remains a significant clinical concern due to the potential risk of disease progression and the limited availability of effective adjunctive therapies during the early phase of the pandemic. Evaluating additional therapeutic agents alongside standard of care is essential to improve clinical outcomes and optimize treatment strategies. This study was designed to assess the role of AVIMAC as an adjunct therapy in managing mild to moderate COVID-19, with the aim of generating clinical evidence to support its safety and effectiveness in routine patient care.